SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13644-13657

  Vieira, Filipa Quintela ^a,b   Costa Pinheiro, Pedro ^a   Almeida Rios, Diogo ^a   Graça, Inês ^a,b   Monteiro Reis, Sara ^a   Simões Sousa, Susana ^c,d   Carneiro, Isa ^a   Sousa, Elsa Joana ^a   Godinho, Maria Inês ^a   Baltazar, Fátima ^c,d   Henrique, Rui ^a,e   Jerónimo, Carmen ^a,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cyclin D2; Histone methyltransferase; Prostate cancer; SET domain; SMYD3

Indexed keywords

CYCLIN D2; HISTONE H4; HISTONE METHYLTRANSFERASE; SET AND MYND DOMAIN CONTAINING PROTEIN 3; UNCLASSIFIED DRUG; CCND2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; SMYD3 PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS ASSAY; ARTICLE; CARCINOGENESIS; CELL CYCLE ASSAY; CELL CYCLE REGULATION; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL VIABILITY ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; PC3 CELL LINE; PHENOTYPE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SMYD3 GENE; TRANSCRIPTION REGULATION; ANIMAL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CYCLIN D2; GENE KNOCKDOWN TECHNIQUES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS;

EID: 84979900432     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3767     Document Type: Article

References (35)

1. Hirst M, Marra MA. Epigenetics and human disease. The international journal of biochemistry & cell biology. 2009; 41:136-146
2. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Human molecular genetics. 2007; . 16 Spec No 1:R28-49
3. Suzuki T, Terashima M, Tange S, Ishimura A. Roles of histone methyl-modifying enzymes in development and progression of cancer. Cancer science. 2013;
4. Albert M, Helin K. Histone methyltransferases in cancer. Seminars in cell & developmental biology. 2010; 21:209-220
5. Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Current cancer drug targets. 2013; 13:558-579
6. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10:457-469
7. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6:731-740
8. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S, Tucker P. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One. 2011; 6:e22290
9. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G, Annan R, Sage J, Garcia BA, Tummino PJ, Gozani O, Kruger RG. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics. 2012; 7:340-343
10. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 2007; 67:10759-10765
11. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer science. 2006; 97:113-118
12. Chen LB, Xu JY, Yang Z, Wang GB. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World journal of gastroenterology: WJG. 2007; 13:5718-5724
13. Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life. 2010; 62:194-199
14. Wang SZ, Luo XG, Shen J, Zou JN, Lu YH, Xi T. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro. BMB Rep. 2008; 41:294-299
15. Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer letters. 2009; 280:78-85
16. Liu C, Xu D, Han H, Fan Y, Schain F, Xu Z, Claesson HE, Bjorkholm M, Sjoberg J. Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation. PLoS One. 2012; 7:e52703
17. Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, Chluba J, Langsley G, Weitzman JB. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012; 72:810-820
18. Liu C, Wang C, Wang K, Liu L, Shen Q, Yan K, Sun X, Chen J, Liu J, Ren H, Liu H, Xu Z, Hu S, Xu D, Fan Y. SMYD3 as an Oncogenic Driver in Prostate Cancer by Stimulation of Androgen Receptor Transcription. Journal of the National Cancer Institute. 2013; 105:1719-1728
19. Siegel R, Ma J, Zou Z, Jemal A,: Cancer statistics, 2014 CA: a cancer journal for clinicians. 201464929
20. DeVita VT, Lawrence TS, Rosenberg SA. (2008). Cancer: Principles & Practice of Oncology: Wolters Kluwer/Lippincott Williams & Wilkins)
21. Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J, Pereira A, Menezes FD, Antunes L, Carneiro I, Oliveira J, Henrique R, Jerónimo C. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocrine-related cancer. 2014; 21:51-61
22. Zeng B, Li Z, Chen R, Guo N, Zhou J, Zhou Q, Lin Q, Cheng D, Liao Q, Zheng L, Gong Y. Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Lett. 2012; 586:3271-3278
23. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F,: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. (Lyon, France: International Agency for Research on Cancer)
24. Tufan AC, Satiroglu-Tufan NL. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Current cancer drug targets. 2005; 5:249-266
25. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Cordeiro M, Bebiano G, Costa P, Palmeirim I, Reis RM, Baltazar F. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-oncology. 2013; 15:172-188
26. Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, Winkler E, Strauss WS, Hibst R, Steiner R, Schrader M, Mertens D, Sultmann H, Wittig R. Matrixdependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia. 2011; 13:579-589
27. Kunzi-Rapp K, Genze F, Kufer R, Reich E, Hautmann RE, Gschwend JE. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. The Journal of urology. 2001; 166:1502-1507
28. Sims RJ 3rd, Reinberg D. From chromatin to cancer: a new histone lysine methyltransferase enters the mix. Nature cell biology. 2004; 6:685-687
29. Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009; 284:19867-19877
30. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006; 84:911-918
31. Kobayashi T, Nakamura E, Shimizu Y, Terada N, Maeno A, Kobori G, Kamba T, Kamoto T, Ogawa O, Inoue T. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells. Biochemical and biophysical research communications. 2009; 387:196-201
32. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen J, Kaulfuss S. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis. 2013; 34:1115-1124
33. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, Bikfalvi A. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:1643-1648
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101-1108
35. Baptista T, Graça I, Sousa EJ, Oliveira AI, Costa NR, Costa-Pinheiro P, Amado F, Henrique R, Jerónimo C. Regulation of histone H2A. Z expression is mediated by sirtuin 1 in prostate cancer. Oncotarget. 2013; 4:1673